HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating for Cytokinetics (NASDAQ:CYTK) and maintained a price target of $90.
September 20, 2024 | 10:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating for Cytokinetics and maintained a price target of $90, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $90 price target by a reputable analyst suggests positive sentiment and confidence in Cytokinetics' future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100